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Abstract: The identification of promising hits and the generation of high quality leads are crucial steps in the early stages 
of drug discovery projects. The definition and assessment of both chemical and biological space have revitalized the 
screening process model and emphasized the importance of exploring the intrinsic complementary nature of classical and 
modern methods in drug research. In this context, the widespread use of combinatorial chemistry and sophisticated 
screening methods for the discovery of lead compounds has created a large demand for small organic molecules that act 
on specific drug targets. 
Modern drug discovery involves the employment of a wide variety of technologies and expertise in multidisciplinary 
research teams. The synergistic effects between experimental and computational approaches on the selection and 
optimization of bioactive compounds emphasize the importance of the integration of advanced technologies in drug 
discovery programs. These technologies (VS, HTS, SBDD, LBDD, QSAR, and so on) are complementary in the sense 
that they have mutual goals, thereby the combination of both empirical and in silico efforts is feasible at many different 
levels of lead optimization and new chemical entity (NCE) discovery. This paper provides a brief perspective on the 
evolution and use of key drug design technologies, highlighting opportunities and challenges. 
Keywords: Drug discovery, ligand-based drug design, high throughput screening, virtual screening, lead discovery. 
INTRODUCTION 
 In the early stages of the drug discovery process, 
chemical libraries varying widely in size and complexity are 
screened for the identification of new hits (i.e., ligands, 
bioactive compounds) [1,2]. The selection of a small fraction 
of compounds with sufficient promise for further 
optimization is a major challenge at this stage of this lengthy 
and risky process [1-3]. Traditional strategies in medicinal 
chemistry are often combined with modern structure- 
(SBDD) and ligand-based drug design (LBDD) approaches 
to explore the vast chemical and biological space as a key 
component in the process of hit-to-lead generation, lead 
optimization and new chemical entity (NCE) discovery [3-
7]. The challenge lies in the integration of these and other 
approaches at different stages in order to improve 
pharmacodynamic and pharmacokinetic properties of lead 
compounds at multiple levels of complexity [8-10]. The aim 
of this perspective is to provide the reader with a brief 
overview of the use and evolution of some key drug 
discovery technologies involved in the processes of hit 
identification and lead discovery, highlighting challenges 
and future directions. 
1. NATURAL PRODUCTS 
 Natural products have been a major source of new 
chemical leads for centuries. In fact, natural products and 
their derivatives correspond to nearly 30% of the small-  
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molecule drugs currently available [11, 12]. The research in 
the field of natural products chemistry has significantly 
evolved to incorporate state-of-the-art multidisciplinary 
approaches, including a variety of methods in medicinal 
chemistry, biochemistry, molecular biology and genomics. 
Moreover, in order to explore the vast chemical and 
biological diversity, several techniques (e.g., miniaturization 
bioassays, coupling chromatographic and spectroscopic 
techniques, higher resolution columns) have experienced 
significant advances in recent years, allowing the 
identification and characterization of several bioactive 
compounds. This complex process consists of a sequence of 
interactive steps, requiring the integration of different 
approaches (Fig. 2). Although the goal is to investigate a 
wide and diverse range of specimen types, the remarkable 
number of species in our planet (e.g., 300,000 – 400,000 
species of plants) requires the use of robust and efficient 
strategies to select and acquire relevant sources of natural 
products [13]. Ethnobotanical studies and bioprospection 
strategies are often used to identify which specimen or parts 
of natural sources are more likely to produce attractive 
bioactive chemotypes. This is very useful for exploring the 
relationships between the genetic biodiversity and the 
environmental factors to chemodiversity [14]. 
 One of the major challenges in natural products drug 
discovery is the identification and selection of valuable lead 
compounds from a number of equally active samples. In 
general, once a sample with promising biological activity has 
been identified, further bioassays-directed fractionation are 
carried out to isolate the active(s) constituent(s). Advances in 
extraction, isolation and purification, as well as in analytical 
and spectroscopic techniques have significantly assisted the 
rapid and reliable structural data elucidation, thereby 
allowing the discovery of novel chemical leads. 
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 A striking example of natural products as a relevant 
source of new lead compounds regards the discovery of 
paclitaxel (Taxol
®
), one of the most powerful and 
commercially successful anticancer drugs, which presents a 
unique mechanism of action as a microtubule-stabilizing 
agent [15]. Paclitaxel was first isolated from the bark of the 
Taxus brevifolia Pacific yew tree as part of a random 
collection expedition for the National Cancer Institute (NCI) 
[16]. Due to its potent cytotoxic activity in several in vivo 
assays and the elucidation of the mechanism of action, 
paclitaxel and its analog docetaxel (Taxotere
®
) are now well-
established anticancer agents useful for breast and ovarian 
carcinoma treatment. However, the structural complexity of 
paclitaxel impairs the development of time and cost-effective 
synthetic routes (e.g., the total synthesis of taxol requires 35 
to 51 steps, with the highest yield of 0.4%) [17]. 
Subsequently, the development of a semi-synthetic route to 
paclitaxel allowed the development of a more efficient 
production process, particularly regarding the decreased need 
for harvesting the yew tree, nonetheless, production still 
depends on plant-based processes with accompanying 
limitations in terms of scale and sustainability [18]. 
Recently, an elegant approach integrating the knowledge of 
the natural products biosynthesis with molecular biology in 
Escherichia coli has significantly enhanced the production of 
taxadiene, the first committed paclitaxel intermediate, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Workflow of the drug discovery process: from hit identification to NCE discovery. 
 
Table 1. Drug Design Approaches for the Identification of Biologically Active Molecules 
 
Approach Century Chemical Technology Advantage Limitation 
Natural Products XIX 
Compound isolation and structural 
characterization 
Remarkable chemical diversity 
and spectrum of biological 
activities 
Mixture of components, 
complex structures and limited 
amounts 
Analog design 
XX 
(1960s) 
Molecular modification, SAR and 
QSAR investigations 
Compounds with in vitro/in vivo 
activity 
Identification of compounds 
with significant 
biological/clinical benefits 
Combinatorial 
Chemistry/High 
Throughput Screening 
(HTS) 
XX 
(1990s) 
Parallel synthesis/ automated 
(large-scale) assays 
Synthesis and biological 
evaluation of large collections of 
compounds 
High rates of false positive 
compounds 
Virtual Screening (VS) 
XX 
(1990s) 
Structure- and ligand-based drug 
design (SBDD) 
Identification of new molecular 
scaffolds 
Accuracy of scoring and 
selection of true binders 
Fragment-Based Drug 
Discovery (FBDD) 
XXI 
Structure- (SBDD) and Ligand-
based drug design (LBDD) 
High quality interaction with the 
target/efficient optimization 
Low sensitive methods, 
availability of structural data 
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approximately 15,000-fold in comparison to the control [19], 
thereby providing greater efficacy and lower cost to new 
anticancer agents. 
 The use of natural products toward the identification of 
quality leads will continue to be a critical factor in drug 
discovery. Considering that inappropriate physicochemical 
properties are a major cause of attrition in drug development, 
the discovery of new molecular scaffolds (lead compounds) 
from small molecule natural products would be extremely 
helpful, especially those with low structural complexity and 
in agreement with the Lipinski’s rule of five (i.e., key 
physicochemical properties that indicate the druglikeness of 
molecules, such as molecular mass < 500 Da; cLogP < 5; 
number of hydrogen-bond donors < 5; number of hydrogen-
bond acceptors < 10) [20]. 
2. ANALOG DESIGN 
 In drug design, the definition of analog consists of a 
molecule that shares structural and pharmacological 
similarities with the original compound [21]. Based on that, 
three categories can be derived: (i) direct analogs – 
molecules possessing chemical and pharmacological 
similarities; (ii) structural analogs – molecules possessing 
chemical similarities; and (iii) functional analogs – 
chemically different molecules exhibiting similar 
pharmacological properties. 
 The first category is characterized by improved versions 
of commercially available drugs in terms of 
pharmacodynamic and/or pharmacokinetic properties. This 
incorporates the so-called “me-too” drugs (i.e., drugs that are 
structurally similar to known drugs), including, for instance, 
the 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) 
reductase inhibitors, also known as statins, and the proton 
pump inhibitor esomeprazole (1), which is the (S)-
enantiomer of the racemic (S), (R)-omeprazole (2). 
Esomeprazole showed clinical advantages over the racemic 
omeprazole, such as higher bioavailability and improved 
inhibition of gastric acid secretion (Fig. 3) [22]. 
 The second category includes compounds designed as 
patentable analogs of the original drug, which, however, 
presented new (and unexpected) biological activities. An 
important example is sildenafil (3), a phosphodiesterase 
type-5 (PDE5) inhibitor, originally designed as an 
antihypertensive agent that reveal unexpected activity on 
male erectile dysfunction during clinical studies (e.g., penile 
erections were a common side effect in the Phase I studies) 
(Fig. 3) [23]. After the approval of sildenafil in 1998 as the 
first oral treatment for erectile dysfunction, scientists at 
Pfizer started to look at other potential uses for this drug. 
The investigations revealed a close relationship between the 
upregulation of PDE5 gene expression and pulmonary 
hypertensive lungs. Later, it was found that the inhibition of 
PDE5 had anti-pulmonary hypertensive activity, with 
selective effects on the pulmonary vascular resistance as 
indicated in the clinical trials. In 2005, the Food and Drug 
Administration (FDA) and the European Medicines Agency 
(EMEA) obtained approval for sildenafil as a new treatment 
for pulmonary arterial hypertension [23]. 
 The last category is known as “functional analogs”, 
where molecules in this class show similar binding 
properties for a common molecular target, regardless of their 
structural differences. Representative examples include, but 
are not limited to: gabazine (4) as a functional analog of (+)-
bicuculline (5) (GABA-A receptor antagonists) [24], and 
zoplicone (6) and zolpidem (7) as functional analogs of 
benzodiazepines (selective benzodiazepine receptors 
agonists) (Fig. 3) [25]. 
 According to the strategy employed, the degree of 
structural similarity to the original scaffold can vary 
considerably, for example, (i) substitution of elements or 
small groups (e.g., isosterism [26]), (ii) swapping fragments 
of molecule (e.g., bioisosterism [27]), or (iii) replacement of 
the original scaffold (e.g., scaffold hopping [28]). Currently, 
the design of analogs is remarkably boosted by in silico 
techniques. The application of chemoinformatics tools 
significantly enhanced the search of analogs and the 
development of structure activity relationships (SAR). 
3. COMBINATORIAL CHEMISTRY AND HIGH 
THROUGHPUT SCREENING 
 The definition and assessment of both chemical and 
biological space have revitalized the screening process 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Schematic steps for lead identification from natural sources. 
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model and emphasized the importance of exploring the 
intrinsic complementary nature of classical and modern 
methods in drug research [1, 2]. Advances in organic 
synthesis along with a wide range of exceptional 
opportunities of pharmaceutical applications provided strong 
motivation for the development of combinatorial chemistry 
as a valuable tool for accelerating the processes of lead 
discovery and optimization [29]. The subsequent widespread 
use of combinatorial chemistry has allowed the generation of 
large collections of small organic molecules available for a 
variety of drug discovery projects [30]. Simultaneously, the 
improvements in robotic and miniaturization associated to 
the advances in genomics and proteomics enabled the 
development of high throughput screening (HTS) as a 
versatile tool for the rapid and large-scale screening of 
chemical libraries [31]. In the pharmaceutical industry, the 
integration of combinatorial chemistry and HTS has become 
one of the most important ways for the identification of 
novel hits and leads in the early stages of the drug discovery 
process [32]. 
 Typically, HTS campaigns identify hundreds or 
thousands of hits (i.e., compounds with in vitro activity 
usually in the low- to mid-micromolar range) for further 
analysis. Depending on the complexity of the assay 
employed, many of the hits can interfere, disrupt or inhibit 
with assay components other than the protein of interest, 
thereby increasing the number of false positives (i.e., 
molecules that appear to be active against the target protein, 
but turn out to be uninteresting compounds) [31]. In line 
with this, intrinsic limitations related to the detection 
methods (in all steps of the analysis process) and 
promiscuous behavior of several compounds of the chemical 
libraries (e.g., aggregation, reactivity), have a considerable 
impact on the quality of the HTS hits. Therefore, several 
strategies have been employed to monitor and control the 
quality and accuracy of the in vitro assays in order to 
minimize the selection of false positives. For example, the 
use of chemoinformatic tools, either previously or in 
connection with HTS methods, has significantly contributed 
to reduce the assay-to-lead attrition rate observed from HTS, 
through the evaluation of the structural diversity and lead- 
and drug-like properties of the library compounds. 
 Since the introduction of HTS in the mid 1990s, much 
emphasis has been put on the increase of both screening 
capacity (i.e., technologies for automation and 
miniaturization) and the size and diversity of the chemical 
libraries. However, recent strategies have been progressively 
moving away from this traditional quantitative perspective to 
a more qualitative paradigm, focusing on the screening of 
representative collections of compounds libraries populated 
with pharmacophore scaffolds that reflect active ligands with 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Examples of direct, structural and functional analogs. 
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lead- or drug-like properties, as well as in highly reliable 
counter screening and validation screening tools (Fig. 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). HTS Workflow. 
 In the early days, HTS technologies were exclusively 
found in the pharmaceutical industry. With the advances in 
the field and the decreased complexity of the approach in 
terms of infrastructure, equipments and human resources, the 
use of HTS has significantly spread worldwide [33]. Indeed, 
over the past years, there was a notable increase in the 
number of screening centers suitably equipped to conduct 
medium- and high-throughput screening activities [34]. 
Several other changes have boosted these developments, 
including price reduction of the automation instrumentation 
sector, popularization of the systems and software, and 
availability of commercial compound library sets. 
 A relevant example of the application of HTS in 
academia can be observed in the search for novel inhibitors 
of Mycobacterium tuberculosis protein tyrosine phosphatase 
B (MtPtpB), an essential virulence factor possessed by all 
mycobacterial species [35]. The HTS was performed at the 
Indiana University Chemical Genomics Core Facility where 
a structurally diverse, pharmacophore-rich, drug-like small 
molecule library of 7500 compounds was screened against 
MtPtpB in 384-well plates [36]. Briefly, the initial screen 
identified 147 hits that showed enzyme inhibition higher 
than 50% at a concentration of 10 μM. Subsequently, counter 
screen assays against a panel of ten protein tyrosine 
phosphatases led to the identification of 40 hits presenting 
highly selective inhibition of MtPtpB. The structural 
similarity of the selective hits was assessed, and two distinct 
structural groups stood out as the most promising MtPtpB 
inhibitors: (i) the piperazinyl-thiophenyl-ethyloxalamide (8 
and 9) derivatives, and (ii) the 2-oxo-1,2-dihydrobenzo-
[cd]indole-6-sulfonamide (10) (Fig. 5). Further biochemical 
evaluation showed that the compounds were either 
competitive (8 and 9) or non-competitive (10) inhibitors of 
MtPtpB, with dissociation constants (Ki) in the low 
micromolar range (Fig. 5). Since the ultimate goal of the 
work was the discovery promising anti-tuberculosis agents, 
the inhibitory activity of the growth of M. tuberculosis in 
macrophages was determined. The results indicated that the 
compounds impaired the ability of mycobacterium to survive 
within macrophages, causing a significant reduction of the 
mycobacterial load in infected cells. 
 It is important to note that the success of HTS strategies 
in the discovery of high quality leads requires a combination 
of factors, including: (i) the design of robust secondary 
assays to validate the hits as active compounds (i.e., true 
binders capable of interacting with the target in a specific 
manner), and (ii) the development of consistent ligand- and 
structure-based in silico methods to efficiently generate 
privilege collections of compounds, avoiding the selection of 
false positives or compounds with insufficient drug-like 
characteristics. 
4. VIRTUAL SCREENING 
 Drug discovery is currently driven by innovation and 
knowledge employing a combination of experimental and 
computational methods. One of the most important 
challenges for the pharmaceutical industry is the 
identification of innovative NCEs from an incredibly large 
reservoir of real and virtual possible compounds [4, 5]. Over 
the past decade, the high-performance computers, 
algorithms, methods and expertise have evolved and 
transformed LBDD and SBDD methods in tools of large 
impact in modern drug discovery [2, 3]. Currently, there are 
two main approaches to VS studies: (i) structure-based 
virtual screening (SBVS), which relies on the knowledge of 
the 3D structures of target proteins to prioritize compounds 
by their complementarity to the binding site; and, (ii) ligand-
based virtual screening (LBVS), where no information on 
the protein is needed, instead, compounds known to bind to 
the protein (or molecules with known biological activity) are 
used as queries to search databases for new molecules 
possessing the same biological activity [1, 2]. The general 
steps employed in VS experiments in order to identify 
promising hits or leads from large collections of compound 
are shown in Fig. (6). This is of great value for researchers in 
small biotechnology companies, academic institutions and 
other organizations involved in drug discovery, in which hit 
and lead discovery are not fuelled by HTS. 
 Although much progress has been made in the generation 
of representative bioactive conformations by automated 
sampling procedures, the scoring functions employed for the 
selection of the most relevant poses are under constant 
development [3, 37]. Scoring functions implemented in 
docking programs make different assumptions and 
simplifications in the evaluation of complexes and do not 
fully account for a number of physical phenomena that 
determine the process of molecular recognition, binding 
affinity and selectivity [38]. For example, ligand-receptor 
binding events are driven by a combination of enthalpic and 
entropic effects, where either entropy or enthalpy can 
dominate specific interactions. In this respect, evolution of 
sophisticated algorithms along with advanced and 
specialized computer hardware will enable enhanced 
description of the molecular phenomena related to ligand 
binding and affinity (e.g., ligand-induced fit, the role of 
water molecules in the binding process, determination of the 
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protonation states, the entropic and enthalpic contributions 
and compensations upon complex formation, so on), thereby 
improving the accuracy of future predictions of novel lead 
candidates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). General steps employed in SBVS and LBVS strategies. 
 In accordance with these advances, VS and other modern 
drug discovery technologies have begun to converge in 
exciting ways. The convergence process will also emphasize 
the importance of integrating computational and 
experimental techniques toward the discovery of high quality 
lead compounds. An example can be seen in the integrated 
medicinal chemistry approach employed toward the 
discovery of new inhibitors of Schistosoma mansoni purine 
nucleoside phosphorylase (SmPNP), a key enzyme involved 
in the purine salvage pathway of S. mansoni, one of the 
causative agents of human schistosomiasis [39-42]. In this 
work, the development of a structure-based pharmacophore 
model for VS of ligands of SmPNP allowed the identification 
of three thioxothiazolidinones derivatives with substantial in 
vitro inhibitory activity against the parasite enzyme (Fig. 7). 
Synthesis, biochemical evaluation and structure-activity 
relationship (SAR) investigations led to the successful 
development of a small set of thioxothiazolidinone 
derivatives harboring a novel chemical scaffold as new 
reversible and competitive inhibitors of SmPNP with affinity 
values in the low micromolar range. The high affinity 
inhibitors (11–13) represent new potential lead compounds 
for further development for the therapy of schistosomiasis 
Fig. (7). 
 The influence of the synergy effects between HTS and 
VS on the selection of hits and lead compounds is a good 
example of the integration of advanced technologies in drug 
discovery programs. Since VS methods were designed for 
the search of large databases of compounds and selection of 
a reduced number of candidates for biological evaluation, 
they can be efficiently merged as complementary tools for 
enriching HTS libraries with drug- and lead-like molecules, 
as well as eliminating compounds that have unwanted 
characteristics for further development. The VS approach 
also provides opportunities for prospective HTS database 
analysis, being capable of extracting useful information for 
database mining. Other applications include, compound-
filtering, database-mining, and rapid analysis of large 
databases subjected to HTS procedures. Finally, these 
investigations are also valuable for the elucidation of the 
structural basis underlying molecular recognition, thereby 
being attractive in lead discovery, drug design and medicinal 
chemistry. 
5. FRAGMENT-BASED DRUG DISCOVERY 
 Fragments are characterized as low molecular weight 
compounds harboring chemical scaffolds  and  functionalities  
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B discovered by HTS. 
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that are commonly observed in drug molecules [43, 44]. 
Fragment-based drug discovery (FBDD) approaches rely on 
the establishment of high-quality interactions between 
molecular fragments and the corresponding binding site 
through the incorporation of successive and specific 
substituents. In this respect, the ligand efficiency (LE) 
concept is an important metric used to judge whether the 
fragment optimization procedure has been conducted 
properly [45]. By definition, LE is the free energy of binding 
(G) divided by the number of heavy atoms (N) (LE = 
G/N) [45]. Alternatively, it can be indicated as the ratio 
between the logarithm of the IC50 (pIC50, where IC50 refers 
the concentration of compound required for 50% inhibition 
of the target enzyme) and the number of heavy atoms (N) in 
the molecule (LE = pIC50/N) [46], or the ratio between the 
logarithm of the inhibition constant (pKi) and the molecular 
weight (MW) of the compound (LE = pKi/MW) [47]. In any 
case, for the purposes of FBDD, the binding affinity of the 
modified molecular fragment should be the sum of the 
individual optimized interactions in the binding site [48]. 
However, even the most advanced scoring functions 
currently available are not able to accurately predict the  
 
binding affinity of bioactive fragments. Therefore, reliable 
experimental methods are necessary to assist the 
development of FBDD approaches [46]. 
 The efficient application of FBDD methods for lead 
discovery faces two main challenges: (i) the continued 
development of robust methods to detect bioactive molecular 
fragments, and (ii) the constant progress of strategies and 
methods for the optimization of the biological and binding 
properties of the selected fragments (e.g., lead generation). 
In order to address these critical issues, structural biology 
methods, such as X-ray crystallographic and nuclear 
magnetic resonance (NMR), have been successfully applied 
[49]. NMR, the first important approach to FBDD, is used to 
detect the chemical shifts induced by the fragment binding, 
and subsequently to determine the experimental binding 
mode of the molecule (Fig. 8). The application of NMR in 
FBDD has prompted the development of a strategy known as 
“SAR by NMR” [50], which has been widely employed with 
a considerable number of successful examples described 
[51]. 
 High-throughput X-ray crystallography methods are also 
efficiently applied in FBDD [52]. The approach starts with  
 
A  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AB  
 
 
 
 
 (11) 
 
 
 
 
 
 (12) 
 
 
 
 
 
 (13) 
 Ki = 7 M Ki = 12 M Ki = 18 M 
Fig. (7). (A) Integrated computational (gray shaded) and experimental (light blue shaded) approaches employed in the identification of novel 
PNP inhibitors from S. mansoni. (B) Representative SmPNP inhibitors. 
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Fig. (8). Key elements in fragment-based drug discovery. 
the screening of libraries composed by hundreds of small 
fragments partitioned into cocktails. The crystals of the 
biological target are separately crystallized (e.g., soaked or 
co-crystallized) with each cocktail, and then the structure is 
solved, allowing the direct detection of the hit (fragment) 
bound to the protein through the electron density map. This 
opens new possibilities for the use of SBDD methods in the 
process of hit-to-lead optimization. In the early stages, the 
approaches employed for fragment-based screening 
generally do not involve crystallographic methods, which 
become essential in the following steps of hit identification 
and lead generation, allowing the complementarity between 
a protein active site and drug-like molecules to be rapidly 
and effectively explored. Pre-screening methods usually 
include NMR, surface plasmon resonance (SPR), isothermal 
titration calorimetry (ITC) and VS (Fig. 8). 
 
 Once a promising fragment is identified (i.e., a ligand 
with macromolar affinity), the process of hit-to-lead 
optimization focus on the optimization of pharmacodynamic 
properties (e.g., affinity, selectivity). However, turning a low 
affinity hit (Kd > 10 μM) into a high affinity ligand is a 
challenging task, which requires significant efforts in 
medicinal chemistry. This process most often entails the 
enhancement of the molecular weight, lipophilicity, number 
of hydrogen bonding groups, rings and rotatable bond counts 
[50]. In addition to the improvements in potency or 
pharmacodynamic properties, the process must also focus on 
the optimization of metabolic stability and oral 
bioavailability of the compounds in order to avoid failures 
during clinical development due to inadequate 
pharmacokinetic properties or off-target side effects [53-55]. 
 A relevant example of the power of FBDD towards the 
identification of high quality leads can be seen in the 
discovery of inhibitors of the molecular chaperone heat 
shock protein 90 (Hsp90), an attractive molecular target for 
the development of anticancer agents [56, 57]. The 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kd = dissociation constant; LE = Ligand Efficiency = –G/N, where N = number of heavy atoms. Cell IC50 = concentration of compound required for 50% 
growth inhibition of the HCT116 cells. 
Fig. (9). HSP90 inhibitors discovered by FBDD. 
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development of the approach started with the screening by 
NMR of a fragment library containing about 1,600 
compounds. Subsequently, 125 hits were progressed into 
high throughput X-ray crystallography. Out of these, 26 
fragment crystal structures were obtained, with the most 
representative compounds (14 and 15) exhibiting affinity in 
the high micromolar range (Fig. 9). The use of SBDD 
methods greatly improved the binding affinity of initial hits, 
leading to extremely potent ligands (nanomolar and 
femtomolar Ki, 16 and 17, respectively), with good ligand 
efficiency and in vitro activity (Fig. 9). It is important to 
emphasize that the hit-to-lead optimization process resulted 
in an outstanding improvement of the affinity for HSP90 by 
over a million-fold with the addition of very few heavy 
atoms. Further lead-to-NCE strategies conducted on (17) 
dramatically enhanced its pharmaceutical properties, as well 
as provided the basis for the elucidation of the mechanism of 
action. The ultimate drug candidate (18) is now under 
evaluation in clinical trials for the treatment of cancer. 
CONCLUSION 
 In the past decades, there has been a remarkable progress 
in the development of state-of-the-art drug discovery 
technologies, with particular emphasis on the processes of 
hit identification and lead generation and optimization. In 
line with the significant scientific advances in the area of 
medicinal chemistry, drug design approaches have become 
much more versatile and powerful. The integration of 
experimental and computational methods continues to play a 
vital role in drug design, creating wonderful opportunities 
and challenges in several stages of the drug discovery and 
development process. Although there are many fundamental 
aspects to be further explored in HTS, combinatorial 
chemistry, SBDD, LBDD, VS, SAR by NMR, FBDD, and 
so on, what is clear is that these and other advances will 
continue to enable and expand the application of these 
approaches in the discovery of NCEs for a vast variety of 
target proteins, and it is expected to remain so for the 
foreseeable future. 
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